Reports Q1 revenue $111.6M, consensus $98.4M. “It’s been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline,” said Chris Peetz, chief executive officer of Mirum. “We’re pleased with the FDA’s approval of LIMARLI’s tablet formulation, which provides more options for the ALGS and PFIC community in the U.S. in the form of a convenient single tablet dose. Our VISTAS study of volixibat in PSC is enrolling well and we expect to complete enrollment in the third quarter of this year. We’re excited to continue our strong execution across our commercial medicines and pipeline throughout the year.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals receives FDA approval for Livmarli tablet formulation
- Strategic Advancements and Market Potential Drive Buy Rating for Mirum Pharmaceuticals
- Mirum Pharmaceuticals partner Takeda receives approval for Livmarli in Japan
- Mirum Pharmaceuticals: Promising Growth Trajectory with Strategic Focus and Pipeline Progress